A Phase 1/2 interventional study of VG801 in Retinal Dystrophy Due to Biallelic ABCA4 Mutations and Stargardt Disease 1, sponsored by VeonGen Therapeutics GmbH. Recruiting at 1 site in China. Open to participants aged 6 Years and older. Per ClinicalTrials.gov, last updated 2026-09-02.
Sponsored by VeonGen Therapeutics GmbH · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a single-arm, open-label, non-randomized, single dose-escalation, first-in-human (FIH) clinical trial to evaluate the safety and preliminary efficacy of VG801 for treatment of patients with retinal dystrophy (Stargardt disease) due to biallelic ABCA4 mutations.
68 studies on the registry are indexed under Stargardt Disease; 27 are open to participants now.
This study's planned enrollment of 18 is below the median of 30 across 43 interventional studies indexed under Stargardt Disease.
Browse Stargardt Disease studies →This is the only study on the registry with VeonGen Therapeutics GmbH as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
To be eligible for study entry, subjects must satisfy all the following criteria:
Exclusion Criteria:
Subjects will be excluded from the study if one or more of the following statements are applicable to either eye:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a single dose of subretinal injection of VG801at Day 0.
Drug: VG801
Administered as specified in the single treatment arm. Study Cohort: Low dose, medium dose and high dose cohort
Adverse Events (AEs) and Serious Adverse Events (SAEs)
Abnormal examination results will be recorded.
Time frame: Baseline to Month 12
Best Corrected Visual Acuity (BCVA)
Abnormal examination results will be recorded.
Time frame: Screening to Month 12
Optical coherence tomography (OCT)
Abnormal examination results will be recorded.
Time frame: Baseline to Month 12
Fundus autofluorescence
Abnormal examination results will be recorded.
Time frame: Baseline to Month 12
Microperimetry
Abnormal examination results will be recorded.
Time frame: Baseline to Month 12
Novel Virtual Reality Visual Test (Exploratory)
Time frame: Baseline to Month 12
Plan to share: Undecided
No publications or documents are linked to this record.
Started Dec 2024 (actual). Primary completion is estimated for Dec 2027, 36 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.